• Introduction
  

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
2. ACTG 5095: A Comparative Study of Three Protease Inhibitor-Sparing Antiretroviral Regimens for the Initial Treatment of HIV Infection
3. ACTG 5097s: Impact of Efavirenz (EFV) on Neuropsychological Performance, Mood and Sleep Behavior in HIV-Positive Individuals
4. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
5. Impact of HIV Infection and HAART on Serum Lipids in Men
6. Efficacy and Safety of Atazanavir With Ritonavir or Saquinavir Versus Lopinavir/Ritonavir in Combination With Tenofovir and One NRTI in Patients Who Have Experienced Virologic Failure to Multiple HAART Regimens: 24-Week Results From BMS AI424-045
7. Continued Reverse Transcriptase Inhibitor Therapy Is Sufficient to Maintain Short-Term Partial Suppression of Multi-Drug Resistant Viremia
8. Analysis From More Than 1,600 Newly Diagnosed Patients With HIV From 17 European Countries Shows That 10% of the Patients Carry Primary Drug Resistance: The CATCH Study
9. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
10. Prognostic Importance of Initial Response in HIV-1 Infected Patients Starting Potent Antiretroviral Therapy: Analysis of Prospective Studies

• Conclusion: Achievements and Limitations
  
• Chart Outlining the Clinical Impact of 2003's Top Reports

Love this article? Hate it? E-mail The Body and tell us what you think!

Introduction

At the close of one year and the beginning of the next, a deep-seated human gene is expressed compelling us to list the top 10 of all things great and small during the past 12 months. The year-end top 10 phenomenon has also found its way into medical education, where experts report what they consider to be the most important developments in their fields. Such lists are, naturally, quite subjective, reflecting the interests of the list-maker, but to a great extent they can also be somewhat redundant as the big news-making studies deservedly find a place on every such list.

What follows is the view of one U.S.-based clinical researcher/clinician on what new information led to a change in the way we practice HIV care -- or, at the very least, made us stop and think long and hard about what we are doing. The accompanying table provides a quick overview of the take-home message from each item on the list, describes how the selected data influenced and advanced our understanding of HIV medicine and, finally, details what remains to be learned.

For a complete index of The Body Pro's HIV JournalViews, click here!

Please note: Knowledge about HIV changes rapidly. Note the date of this article, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

© 2004 Body Health Resources Corporation